Tous Actualités
Suivre
Abonner Epigenomics AG

Epigenomics AG

EANS-Adhoc: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Not for distribution in the United States. Epigenomics AG Places Maximum Number of New Shares in Capital Increase ...

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
Company Information/Molecular diagnostics
30.03.2010
Berlin, Germany, March 30, 2010 - Epigenomics AG (Frankfurt Prime 
Standard: ECX; ISIN: DE000A0BVT96) today successfully completed the 
placement of 14,697,361 new ordinary bearer shares within a rights 
offering representing the entire authorized capital available. The 
new shares were placed at the subscription price of EUR 2.25 per new 
share resulting in gross proceeds of about EUR 33.1 million. The 
rights offering started on March 15, 2010 and ended on March 29, 
2010.
The subscription rate in the  transaction  was  46.2%  equalling  
6,789,613  new shares. The remaining  7,907,748  unsubscribed  new  
shares  were  sold  at  the subscription price to retail investors as
part of a public offering  in  Germany and Austria, as well as to  
selected  institutional  investors  in  Germany  and abroad.  This  
public  offering  was  significantly   oversubscribed,   enabling 
Epigenomics AG to place the entire number of new shares. A sizeable  
portion  of the unsubscribed new shares were placed with funds 
managed  by  Abingworth  LLP, London, United Kingdom, that  in  
addition  to  exercising  pre-emptive  rights, increased their stake 
in Epigenomics  AG  to  become  the  largest  shareholders after the 
capital increase.
ICF Kursmakler AG (Frankfurt, Germany) acted  as  sole  lead  manager
and  sole underwriter.
The registration  of  the  implementation  of  the  capital  increase
with  the commercial register (Handelsregister) and the admission of 
the  new  shares  to the regulated market (regulierter  Markt),  
Prime  Standard,  of  the  Frankfurt Stock Exchange is expected on or
around March  31,  2010.  Trading  in  the  new shares is expected to
begin on or around April 1, 2010.
With the registration of the implementation of the capital  increase 
the  total issued share capital of Epigenomics increases  from  EUR  
29,394,724.00  to  EUR 44,092,085.00.
Epigenomics AG intends to use the net proceeds from the offering to 
finance its current operations and to build and strengthen the 
marketing, sales, and distribution capacities for its products, to 
support ongoing and new product development for its business in 
cancer screening, diagnosis, disease progression and recurrence 
monitoring, and assessment of disease prognosis and in this areas in 
particular the funding of further R&D, clinical trials, regulatory 
approvals and market introduction of its products that are currently 
in its product pipeline as well as enhancing and strengthening 
capabilities related to regulatory affairs and clinical trials, 
further improvement of the DNA methylation technology, additional 
in-licensing agreements and strengthening its intellectual property 
portfolio, as well as for general corporate purposes.
Disclaimer
This publication is not an offer of any securities for sale  or  a  
solicitation of an offer to purchase any securities.
This document is not an offer of securities for sale or  a  
solicitation  of  an offer to purchase securities in the United 
States. The shares of Epigenomics  AG (the "Shares") have not been 
registered under the U.S. Securities Act  of  1933, as amended (the 
"Securities Act") and may not be offered or sold in  the  United 
States unless registered under the Securities Act or pursuant  to  an
exemption from such registration. There will be no public offering of
the  Shares  in  the United States and the Shares will not be 
registered under the Securities Act.
This document is only being distributed to and is only directed at  
(i)  persons who are outside the United Kingdom or (ii) to investment
professionals  falling within Article 19(5) of the Financial Services
and Markets Act  2000  (Financial Promotion) Order 2005 (the "Order")
or (iii) high net worth entities, and  other persons to  whom  it  
may  lawfully  be  communicated,  falling  within  Article 49(2)(a) 
to (d) of the Order (all such persons together  being  referred  to  
as "relevant persons"). The Shares are  only  available  to,  and  
any  invitation, offer or agreement to subscribe, purchase or 
otherwise acquire  such  securities will be engaged in only  with,  
relevant  persons.  Any  person  who  is  not  a relevant person 
should not act or rely on this document or any of its contents.
This communication expressly  or  implicitly  contains  certain  
forward-looking statements concerning Epigenomics AG and its 
business. Such  statements  involve certain known and unknown risks, 
uncertainties and  other  factors  which  could cause the actual 
results, financial condition, performance  or  achievements  of 
Epigenomics AG to be materially different from any future  results,  
performance or  achievements  expressed  or  implied  by  such  
forward-looking  statements. Epigenomics AG is providing this 
communication as of  this  date  and  does  not undertake to update 
any forward-looking statements contained herein as a  result of new 
information, future events or otherwise.
The offer in Germany and Austria was made exclusively by means  of  
and  on  the basis of a prospectus published and available free of 
charge at  Epigenomics  AG (fax number +49 30 24345 555) and ICF 
Kursmakler AG (fax number  +49  69  92877- 222).
Contact:
Epigenomics AG
Dr. Achim Plum
Senior VP Corporate Development
Kleine Präsidentenstr. 1
10178 Berlin
Germany
+49 30 24345 368 (phone)
+49 30 24345 555 (fax) 
achim.plum@epigenomics.com
end of announcement                               euro adhoc

Further inquiry note:

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade

Plus de actualités: Epigenomics AG
Plus de actualités: Epigenomics AG
  • 25.03.2010 – 15:01

    EANS-News: Epigenomics AG invites to Annual Press Conference and Analyst Meeting 2010

    Not for distribution in the United States of America Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Molecular diagnostics Subtitle: Not for distribution in the United States of America Berlin, Germany, and Seattle, WA, USA, March 25, 2010 (euro adhoc) - ...

  • 12.03.2010 – 08:31

    EANS-News: Epigenomics AG: Financial Results for the Fiscal Year 2009

    Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Financial Figures/Balance Sheet/Molecular diagnostics Press release, Berlin, Germany, and Seattle, WA, U.S.A., March 12, 2010 (euro adhoc) - Key Figures and Financial Highlights: * Full year revenue increased to EUR 4.3 million * ...

  • 11.03.2010 – 16:01

    EANS-News: Epigenomics AG Receives Allowance for Key Technology Patent in Japan

    Patent broadly covers HeavyMethyl, a core technology of Epigenomics’ molecular diagnostic products Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Patents, Copyright & Trademarks/Molecular diagnostics Subtitle: Patent broadly covers HeavyMethyl, a core technology of Epigenomics’ ...